文献速递骨软组织肉瘤与黑色素瘤

瑞戈非尼治疗既往治疗后进展的c-KIT突变转移性恶性黑色素瘤疗效的II期研究(KCSG-UN-14-13)

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).
PubMed 文献 · Eur J Cancer · 2023-08-28

这项多机构、II期、单臂研究评估瑞戈非尼治疗既往至少一线系统治疗后进展的c-KIT突变转移性黑色素瘤患者的疗效。共纳入23例患者,口服瑞戈非尼160 mg每日一次,用3周停1周(4周周期)。8周疾病控制率为73.9%,客观缓解率为30.4%,中位无进展生存期7.1个月,中位总生存期21.5个月,最常见不良事件为皮肤反应(掌跖红斑感觉异常综合征52.2%),3级不良事件发生率为39.1%。

要点

  • 瑞戈非尼二线或后线治疗c-KIT突变转移性黑色素瘤的8周疾病控制率为73.9%。
  • 客观缓解率为30.4%(7/23),其中完全缓解2例(8.7%),部分缓解5例(21.7%)。
  • 中位无进展生存期7.1个月,中位总生存期21.5个月,中位随访15.7个月。

核心结论

  • 瑞戈非尼在二线或后线治疗中,对携带c-KIT突变的转移性黑色素瘤患者显示出显著活性。

研究设计与样本

  • 多机构、II期、单臂研究,纳入23例c-KIT突变阳性、至少一线系统治疗后进展的转移性黑色素瘤患者。
  • 患者接受口服瑞戈非尼160 mg每日一次,用3周停1周(4周周期)。
  • 主要终点为疾病控制率(DCR),次要终点为安全性、客观缓解率(ORR)、无进展生存期(PFS)和总生存期(OS)。

主要发现

  • c-KIT突变常见于外显子11(14/23,60.9%),其次为外显子13(5例,21.7%)、外显子17(5例,21.7%)和外显子9(2例,8.7%)。
  • 8周疾病控制率为73.9%,其中完全缓解2例(8.7%)、部分缓解5例(21.7%)、疾病稳定10例(43.5%)。
  • 客观缓解率为30.4%(7/23)。
  • 中位随访期15.7个月(95%置信区间[CI],9.6-21.3),中位总生存期21.5个月(95%CI,15.1-27.9),中位无进展生存期7.1个月(95%CI,5.0-9.2)。
  • 在选定患者中进行的循环肿瘤DNA分析显示,与组织肿瘤突变谱的c-KIT一致性高(85.7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: c-KIT mutations are found in approximately 15% of patients with malignant melanoma in the Asian population. Regorafenib, an oral multikinase inhibitor, acts against both wild-type and mutant KIT. OBJECTIVE: This multi-institutional, phase II, single-arm study aimed to evaluate the efficacy of regorafenib against metastatic malignant melanoma harbouring c-KIT mutations. METHODS: Patients with metastatic melanoma positive for c-KIT mutations, upon progression after at least one line of systemic treatment, were enroled. Patients received oral regorafenib 160 mg once daily for 3 weeks (4-week cycle). The primary endpoint was disease control rate (DCR), and secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In total, 23 patients were enrolled. c-KIT mutations were frequently reported in exon 11 (14/23, 60.9%), followed by exons 13, 17, and 9 in 5 (21.7%), 5 (21.7%), and 2 (8.7%) patients, respectively. DCR at 8 weeks was 73.9%, with 2 patients (8.7%) achieving complete response, 5 (21.7%) achieving partial response, and 10 (43.5%) showing stable disease. ORR was 30.4% (7/23). The median follow-up period was 15.7 months (95% confidence interval [CI], 9.6-21.3), and median OS and PFS were 21.5 months (95% CI, 15.1-27.9) and 7.1 months (95% CI, 5.0-9.2), respectively. Circulating tumour DNA analysis in selected patients showed high c-KIT correlation (85.7%) with tissue-based tumour mutational profiles. The most common adverse events (AEs) were skin reactions, including palmar-plantar erythrodysesthesia (52.2%), and grade 3 AEs were reported in 39.1% (9/23) of the patients. CONCLUSION: Regorafenib in second- or later-line settings demonstrated significant activity in patients with metastatic melanoma harbouring c-KIT mutations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim KH, Jung M, Lee HJ, et al. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13). Eur J Cancer. 2023. PMID: 37741071. doi:10.1016/j.ejca.2023.113312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。